Clinical Evidence: What The Trials Actually Show
Wegovy V Saxenda: Understanding The Clinical Trial Evidence
When comparing Wegovy versus Saxenda, the most compelling differences emerge from their respective clinical trial programmes. Wegovy's STEP trials demonstrated that patients taking semaglutide alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, whilst Saxenda's SCALE trials showed patients achieved around 8% average weight loss with liraglutide. These results reflect different trial designs, populations, and endpoints, making direct head-to-head comparisons challenging without proper clinical context.
The evidence base for Wegovy V Saxenda extends beyond weight loss percentages to include cardiovascular outcomes and long-term sustainability data. Wegovy's SELECT trial revealed a 20% reduction in major cardiovascular events, whilst Saxenda demonstrated its own cardiovascular safety profile through the LEADER study. Both prescription-only medicines require clinical assessment to determine individual suitability, as published trial results may not reflect personal outcomes.
Wegovy V Saxenda Pricing: UK Treatment Costs Compared
Understanding the financial commitment when weighing Wegovy versus Saxenda helps inform your treatment decision. Wegovy pricing at EverydayMeds starts with our 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to maintenance 2.4mg (£209.99). Our bundle options like the Intro Trio (0.25mg, 0.5mg and 1mg) provide three months of step-up treatment for £299.99, offering supply convenience without multiple orders.
Saxenda pricing follows a different structure due to its daily injection requirement, typically requiring multiple pens monthly compared to Wegovy's once-weekly dosing. New customers can apply discount code FIRST40 at checkout, whilst returning patients use DOSE25 to access our best available pricing. Both Wegovy and Saxenda are available from EverydayMeds following clinical assessment, with your prescriber helping determine which treatment timeline and cost structure suits your circumstances.
STEP Trial Evidence For Wegovy V Saxenda Comparisons
The landmark STEP 1 trial, published by Wilding et al. in the New England Journal of Medicine 2021, provides crucial evidence when evaluating Wegovy versus Saxenda options. In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, with STEP 3 showing around 16% when combined with intensive behavioural therapy. STEP 5 demonstrated sustainability with clinically studied weight loss maintained at two years.
Saxenda's clinical foundation comes from the SCALE programme, showing different but meaningful results in its own patient populations. When comparing Wegovy V Saxenda trial data, it's essential to recognise that these studies used different methodologies, inclusion criteria, and measurement timepoints. Your individual response to either treatment may vary from published averages, which is why clinical assessment remains crucial before starting either prescription-only medicine.
How Wegovy V Saxenda Mechanisms Differ In Practice
Both treatments work as GLP-1 receptor agonists, mimicking natural fullness hormones to reduce appetite and promote satiety after smaller meals. However, the Wegovy versus Saxenda comparison reveals important practical differences in their implementation. Wegovy uses semaglutide delivered once weekly through a FlexTouch pen, whilst Saxenda provides daily liraglutide injections requiring more frequent administration. This dosing difference affects treatment compliance, lifestyle integration, and the psychological aspect of daily versus weekly injection routines. Both may reduce food cravings by working on brain appetite centres, but the sustained weekly action of Wegovy versus the daily peaks of Saxenda creates different therapeutic experiences for patients.
Wegovy V Saxenda: UK Ordering Process At EverydayMeds
Accessing either treatment through EverydayMeds begins with our streamlined 3-minute online clinical assessment, designed to evaluate your suitability for Wegovy versus Saxenda based on current medical guidelines. Following submission, our GPhC-registered clinical team (#9012878) reviews your information within standard 3 working days, or 24 hours with express service. Once approved, both treatments are dispatched via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements crucial for medication efficacy. Our process ensures you receive genuine, licensed products whether choosing Wegovy or Saxenda, with full prescriber support throughout your treatment journey. The assessment considers your BMI, medical history, and treatment preferences to guide appropriate selection between these prescription-only medicines.
Storage And Practical Considerations: Wegovy V Saxenda
Practical storage differences between Wegovy and Saxenda may influence your treatment choice, particularly if you travel frequently or have limited refrigerator space. Wegovy offers significant convenience advantage, remaining stable at room temperature below 30°C for up to 6 weeks once removed from refrigeration, compared to Saxenda's shorter room temperature tolerance. Both require initial refrigerated storage at 2-8°C before first use, but Wegovy's extended temperature flexibility suits varied lifestyles better. The FlexTouch pen design is consistent across both treatments, though Wegovy's weekly dosing means fewer injection events and less frequent pen replacement. Dose escalation is mandatory for both treatments, but Wegovy's monthly increases versus Saxenda's weekly adjustments create different treatment rhythms requiring consideration in your Wegovy versus Saxenda evaluation.
UK Weight Management Outcomes: Real-World Wegovy V Saxenda Results
Beyond clinical trial data, understanding how Wegovy versus Saxenda performs in UK healthcare settings provides valuable insight for treatment selection. NHS experience with both treatments shows varying individual responses, with some patients responding better to weekly semaglutide whilst others prefer daily liraglutide's more frequent dosing pattern. Weight management success with either option depends heavily on concurrent lifestyle modifications, including reduced-calorie diet and increased physical activity as mandated by MHRA licensing conditions.
The NICE TA875 recommendation for Wegovy within specialist weight management programmes reflects growing UK clinical confidence in weekly semaglutide therapy. However, Saxenda maintains its established role for patients who prefer daily dosing control or have specific clinical considerations favouring liraglutide. Both treatments require long-term commitment, as STEP trial extensions showed patients regained approximately two-thirds of lost weight within one year of stopping treatment, emphasising that weight management represents an ongoing clinical commitment rather than short-term intervention.
Making Your Wegovy V Saxenda Decision With EverydayMeds
Choosing between Wegovy and Saxenda requires careful consideration of clinical evidence, practical factors, and personal preferences, which our experienced clinical team can guide you through. Both prescription-only medicines are available at EverydayMeds with transparent pricing, from Wegovy's £79.99 starter dose to our comprehensive bundle options designed for treatment continuity. New customers can use discount code FIRST40 at checkout, whilst returning patients benefit from DOSE25 pricing. Our GPhC-registered pharmacy (#9012878) ensures you receive authentic, properly stored medications regardless of your Wegovy versus Saxenda choice. The clinical assessment process evaluates your individual circumstances, helping determine which treatment's evidence base, dosing schedule, and practical considerations align with your weight management goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
